nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

15.03.2024 | General Gynecology

Evaluation of a scoring system to predict treatment success with single-dose methotrexate in ectopic pregnancy

verfasst von: Ali Selcuk Yeniocak, Can Tercan, Emrah Dagdeviren, Onur Arabacı, Emine Elif Genc

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study sought to assess the efficacy of a newly developed scoring system in predicting treatment outcomes for ectopic pregnancy among patients undergoing single-dose methotrexate therapy. The primary research question centered on the reliability and predictive accuracy of objective parameters in determining methotrexate therapy success.

Methods

Conducted as a retrospective single-center cohort study, data from 172 ectopic pregnancy patients treated with methotrexate between January 2021 and January 2023 were analyzed. Parameters including adnexal mass size, peritoneal fluid presence, yolk sac identification, endometrial thickness, ectopic pregnancy location, and initial B-hCG levels were meticulously evaluated for their association with treatment outcomes.

Results

Following the exclusion of 21 emergency surgery cases, the final analysis comprised 151 patients. Notable associations were observed between specific parameters (fetal cardiac activity, adnexal mass size > 3.5 cm, peritoneal fluid presence, yolk sac identification, endometrial thickness > 10 mm, and initial B-hCG levels) and treatment outcomes (p < 0.001). Additionally, the novel scoring system demonstrated promising predictive performance. At a cutoff of 2.50, it achieved a sensitivity of 91.7% and a specificity of 59.7%. Increasing the cutoff to 3.50 resulted in a sensitivity of 94.0%, with a specificity of 46.3%.

Conclusion

Objective parameters, particularly those integrated into the developed scoring system, exhibited substantial associations with methotrexate therapy outcomes in ectopic pregnancy. These findings underscore the potential of an objective scoring model to significantly influence clinical decision-making in therapy, offering avenues for enhanced prognostication and patient care in treatment outcomes.

Van Den Eeden SK, Shan J, Bruce C, Glasser M (2005) Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstetr Gynecol 105(5 Pt 1):1052–1057. https://doi.org/10.1097/01.AOG.0000158860.26939.2dCrossRef

Bouyer J, Coste J, Shojaei T, Pouly JL, Fernandez H, Gerbaud L, Job-Spira N (2003) Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol 157(3):185–194. https://doi.org/10.1093/aje/kwf190CrossRefPubMed

Du T, Chen H, Fu R, Chen Q, Wang Y, Mol BW, Kuang Y, Lyu Q (2017) Comparison of ectopic pregnancy risk among transfers of embryos vitrified on day 3, day 5, and day 6. Fertil Steril 108(1):108-116.e1. https://doi.org/10.1016/j.fertnstert.2017.05.027CrossRefPubMed

Lipscomb GH (2007) Medical therapy for ectopic pregnancy. Semin Reprod Med 25(2):93–98. https://doi.org/10.1055/s-2007-970048CrossRefPubMed

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology (2018) ACOG Practice Bulletin No. 193: tubal ectopic pregnancy. Obstetr Gynecol 131(3):e91–e103. https://doi.org/10.1097/AOG.0000000000002560

Kelly H, Harvey D, Moll S (2006) A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstetr Gynecol 107(2 Pt 2):439–441. https://doi.org/10.1097/01.AOG.0000172374.72125.3eCrossRef

Teal SB (2006) A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstetr Gynecol 107(6):1420–1421CrossRef

Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41(1):36–51. https://doi.org/10.1002/1097-0142(197801)41:1%3c36::aid-cncr2820410108%3e3.0.co;2-iCrossRefPubMed

Dudley PS, Heard MJ, Sangi-Haghpeykar H, Carson SA, Buster JE (2004) Characterizing ectopic pregnancies that rupture despite treatment with methotrexate. Fertil Steril 82(5):1374–1378. https://doi.org/10.1016/j.fertnstert.2004.03.066CrossRefPubMed

10.

Menon S, Colins J, Barnhart KT (2007) Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 87(3):481–484. https://doi.org/10.1016/j.fertnstert.2006.10.007CrossRefPubMed

11.

Mol F, Mol BW, Ankum WM, van der Veen F, Hajenius PJ (2008) Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 14(4):309–319. https://doi.org/10.1093/humupd/dmn012CrossRefPubMed

12.

Corsan GH, Karacan M, Qasim S, Bohrer MK, Ransom MX, Kemmann E (1995) Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Hum Reprod 10(10):2719–2722. https://doi.org/10.1093/oxfordjournals.humrep.a135774CrossRefPubMed

13.

Kumtepe Y, Kadanali S (2004) Medical treatment of ruptured with hemodynamically stable and unruptured ectopic pregnancy patients. Eur J Obstetr Gynecol Reprod Biol 116(2):221–225. https://doi.org/10.1016/j.ejogrb.2004.03.003CrossRef

14.

Barnhart KT, Gosman G, Ashby R, Sammel M (2003) The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstetr Gynecol 101(4):778–784. https://doi.org/10.1016/s0029-7844(02)03158-7CrossRef

15.

Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW (1998) Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstetr Gynecol 178(6):1354–1358. https://doi.org/10.1016/s0002-9378(98)70343-6CrossRef

16.

Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW (1999) Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 341(26):1974–1978. https://doi.org/10.1056/NEJM199912233412604CrossRefPubMed

17.

Vermesh M, Graczykowski JW, Sauer MV (1990) Reevaluation of the role of culdocentesis in the management of ectopic pregnancy. Am J Obstetr Gynecol 162(2):411–413. https://doi.org/10.1016/0002-9378(90)90397-pCrossRef

18.

Bixby S, Tello R, Kuligowska E (2005) Presence of a yolk sac on transvaginal sonography is the most reliable predictor of single-dose methotrexate treatment failure in ectopic pregnancy. J Ultrasound Med 24(5):591–598. https://doi.org/10.7863/jum.2005.24.5.591CrossRefPubMed

19.

da Costa SR, Elito J Jr, Han KK, Camano L (2004) Endometrial thickness as an orienting factor for the medical treatment of unruptured tubal pregnancy. Acta Obstetr Gynecol Scand 83(3):289–292. https://doi.org/10.1111/j.0001-6349.2004.0387.xCrossRef

20.

Levin G, Meyer R, Dior U, Gilad R, Benshushan A, Shushan A, Rottenstreich A (2020) Outcome of methotrexate treatment for ectopic pregnancies among obese women. J Gynecol Obstetr Hum Reprod 49:101790. Advance online publication. https://doi.org/10.1016/j.jogoh.2020.101790

21.

Bonin L, Pedreiro C, Moret S, Chene G, Gaucherand P, Lamblin G (2017) Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: a comparative study of 400 cases. Eur J Obstetr Gynecol Reprod Biol 208:23–30. https://doi.org/10.1016/j.ejogrb.2016.11.016CrossRef

22.

Elito J Jr, Reichmann AP, Uchiyama MN, Camano L (1999) Predictive score for the systemic treatment of unruptured ectopic pregnancy with a single dose of methotrexate. Int J Gynaecol Obstetr 67(2):75–79. https://doi.org/10.1016/s0020-7292(99)00114-9CrossRef

23.

Kahyaoglu S, Turgay I, Gocmen M, Sut N, Batioglu S (2006) A new predictive scoring system including shock index for unruptured tubal pregnancy patients. Eur J Obstetr Gynecol Reprod Biol 126(1):99–103. https://doi.org/10.1016/j.ejogrb.2005.09.006CrossRef

24.

Morlock RJ, Lafata JE, Eisenstein D (2000) Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstetr Gynecol 95(3):407–412. https://doi.org/10.1016/s0029-7844(99)00548-7CrossRef

25.

Hajenius PJ, Mol F, Mol BW, Bossuyt PM, Ankum WM, van der Veen F (2007) Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007(1):CD000324. https://doi.org/10.1002/14651858.CD000324.pub2

26.

American College of Obstetricians and Gynecologists (2008) ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstetr Gynecol 111(6):1479–1485. https://doi.org/10.1097/AOG.0b013e31817d201e

27.

Practice Committee of American Society for Reproductive Medicine (2013) Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril 100(3):638–644. https://doi.org/10.1016/j.fertnstert.2013.06.013CrossRef

28.

Willner N, Storch S, Tadmor T, Schiff E (2014) Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. Eur J Clin Pharmacol 70(3):261–263. https://doi.org/10.1007/s00228-013-1608-3CrossRefPubMed

29.

Nazac A, Gervaise A, Bouye J, de Tayrac R, Capella-Allouc S, Fernandez H (2003) Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstetr Gynecol 21(2):181–185. https://doi.org/10.1002/uog.9CrossRef

30.

Tzafettas JM, Stephanatos A, Loufopoulos A, Anapliotis S, Mamopoulos M, Kalogeropoulos A (1999) Single high dose of local methotrexate for the management of relatively advanced ectopic pregnancies. Fertil Steril 71(6):1010–1013. https://doi.org/10.1016/s0015-0282(99)00147-8CrossRefPubMed

31.

Gamzu R, Almog B, Levin Y, Pauzner D, Lessing JB, Jaffa A, Bar-Am A (2002) The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate. Hum Reprod 17(10):2585–2587. https://doi.org/10.1093/humrep/17.10.2585CrossRefPubMed

Titel: Evaluation of a scoring system to predict treatment success with single-dose methotrexate in ectopic pregnancy
verfasst von: Ali Selcuk Yeniocak
Can Tercan
Emrah Dagdeviren
Onur Arabacı
Emine Elif Genc
Publikationsdatum: 15.03.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-024-07458-6

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Evaluation of a scoring system to predict treatment success with single-dose methotrexate in ectopic pregnancy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Global prevalence of major depressive disorder, generalized anxiety, stress, and depression among infertile women: a systematic review and meta-analysis

Analysis of related factors influencing postoperative recurrence of adenomyosis treated with HIFU

Retraction Note to: Fetal fibronectin (Quick Check fFN test®) for detection of premature rupture of fetal membranes

Comparison of pregnancy outcomes in women with normal ovarian response to the gonadotropin-releasing hormone agonist protocol using different trigger methods: a single-center retrospective cohort study based on propensity score matching

The effect of injectable platelet rich fibrin as a nonsurgical treatment of the female stress urinary incontinence

Awareness, knowledge and attitudes of human papillomavirus infection, screening and vaccination: a survey study in Greece

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie